|
| Effect of Reduqing to intestinal endotoxemia in hepatic failure |
| Hits 1717 Download times 1336 Received:October 11, 2016 |
| View Full Text View/Add Comment Download reader |
| DOI
10.11656/j.issn.1672-1519.2017.02.07 |
| Key Words
hepatic failure;intestinal endotoxemia;extracorporeal blood purification;blood purification in vivo |
| Author Name | Affiliation | E-mail | | CHEN Peng | Department of Chronic Liver Diseases, Tianjin Second People's Hospital, Tianjin 300192, China | | | CAO Wu-kui | Department of Chronic Liver Diseases, Tianjin Second People's Hospital, Tianjin 300192, China | chenpeng0122@sina.cn |
|
| Abstract
|
| [Objective] To investigate the efficacy of "extracorporeal blood purification" combining with "blood purification in vivo" chinese drugs pharmaceutics "Reduqing" in the treatment on intestinal endotoxemia of hepatic failure.[Methods] The 50 cases of hepatic failure were distinguished by using a single application of "extracorporeal blood purification" (group I), the application of "Reduqing" before "extracorporeal blood purification" (groupⅡ) and "Reduqing" added during the treatment of "extracorporeal blood purification" (groupⅢ). Levels of plasma endotoxin (ET), lipid peroxide (LPO), tumor necrosis factor α (TNF-α), total bilirubin (TBIL) and mortality were observed before and after treatment.[Results] Incidence of endotoxemia in hepatic failure patients was 100%, levels of ET, LPO and TBIL decreased more significantly than before treatment in three groups of liver failure patients, compared with before treatment, TNF-α in groupⅡ decreased significantly after treatment. ET, LPO and TNF-α in group Ⅱ decreased significantly than the groupⅠ, group Ⅲ. Although the general average of TBIL in groupⅡ was the lowest, the difference between two other groups was not statistically significant (P>0.05). Mortality in groupⅠand Ⅲ were 75% and 68.75% respectively, and in groupⅡ was 44.44%. Although the mortality in groupⅠand Ⅲ decreased, differences were not statistically significant (P>0.05).[Conclusion] There were different degrees of endotoxemia in patents in liver failure group. "In vivo and extracorporeal blood purification" therapy, whether used alone or in combination, plays a significant role in improving ETM and reduce the inflammatory in hepatic cells. "Reduqing" combining with "extracorporeal blood purification" used in early stage is contributed to a lower ET, reducing LPO and TNF-α. It can also improve liver function, and has a positive significance on reducing mortality by using in early stage. |
|
|
|
|
|
|
|
